Patents by Inventor Reiner L. Gentz

Reiner L. Gentz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to human tumor necrosis factor receptor TR9
    Patent number: 6919078
    Abstract: The present invention relates to a novel member of the tumor necrosis factor family of receptors. In particular, isolated nucleic acid molecules are provided encoding the human TR9 receptor. TR9 polypeptides are also provided as are antibodies, vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR9 receptor activity.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: July 19, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Guo-Liang Yu, Ping Fan, Reiner L. Gentz
  • Antibodies to protein HPMBQ91
    Patent number: 6919433
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: July 19, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Craig A. Rosen, Yi Li, Zhizhen Zeng, Hla Kyaw, Carrie L. Fischer, Haodong Li, Daniel R. Soppet, Reiner L. Gentz, Ying-Fei Wei, Paul A. Moore, Paul E. Young, John M. Greene, Ann M. Ferrie, Gregg A. Hastings
  • Tissue factor pathway inhibitor-3
    Patent number: 6916629
    Abstract: The present invention relates to a novel TFPI-3 protein which is a member of the tissue factor protease inhibitor family. In particular, isolated nucleic acid molecules are provided encoding human TFPI-3 proteins. TFPI-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TFPI-3 activity. Also provided are diagnostic methods for detecting hemostasis system-related disorders and therapeutic methods for treating hemostatis system-related disorders.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: July 12, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Tsu-An Hsu, Craig A. Rosen, Jian Ni
  • Keratinocyte growth factor-2
    Patent number: 6916786
    Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: July 12, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Pablo Jimenez, D. Roxanne Duan, Mark A. Rampy, Donna Mendrick, Jun Zhang, Jian Ni, Paul A. Moore, Timothy A. Coleman, Joachim R. Gruber, Patrick J. Dillon, Reiner L. Gentz
  • Keratinocyte growth factor-2
    Patent number: 6903072
    Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.
    Type: Grant
    Filed: July 1, 1999
    Date of Patent: June 7, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Pablo Jimenez, D. Roxanne Duan, Mark A. Rampy, Donna Mendrick, Jun Zhang, Jian Ni, Paul A. Moore, Timothy A. Coleman, Joachim R. Gruber, Patrick J. Dillon, Reiner L. Gentz
  • Death domain containing receptor 4
    Patent number: 6902910
    Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: June 7, 2005
    Assignees: Human Genome Sciences, Inc., The Regent of the University of Michigan
    Inventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
  • Pancreas-derived plasminogen activator inhibitor
    Patent number: 6893870
    Abstract: The present invention relates to a novel member of the plasminogen activator inhibitor protein family. In particular, isolated nucleic acid molecules are provided encoding the pancreas-derived plasminogen activator inhibitor protein. Pancreas-derived plasminogen activator inhibitor polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to methods for treating physiologic and pathologic disease conditions and diagnostic methods for detecting pathologic disorders.
    Type: Grant
    Filed: July 29, 2003
    Date of Patent: May 17, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Steven M. Ruben, Y. Eric Shi
  • Death domain containing receptor 5 antibodies
    Patent number: 6872568
    Abstract: The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: March 29, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Guo-Liang Yu, Craig A. Rosen
  • Keratinocyte growth factor-2 formulations
    Patent number: 6869927
    Abstract: The invention is directed to liquid and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivatives thereof. This invention further relates to the formulation of KGF-2 for therapeutic use, for example, to promote or accelerate wound healing.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: March 22, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Arvind Chopra, Parveen Kaushal, Thomas Spitznagel, Edward Unsworth, Fazal Khan
  • Human endometrial specific steroid-binding factor I, II and III
    Patent number: 6861226
    Abstract: The invention relates to hESF I, II and III polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.
    Type: Grant
    Filed: November 6, 2001
    Date of Patent: March 1, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Guo-Liang Yu, Reiner L. Gentz
  • Synferon
    Patent number: 6843988
    Abstract: The present invention relates to a novel Synferon protein which is a member of the interferon family. In particular, isolated nucleic acid molecules are provided encoding a synthetic interferon polypeptide, called “Synferon”. Synferon polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Synferon activity. Also provided are therapeutic methods for treating immune system-related disorders.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: January 18, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Henrik S. Olsen, Reiner L. Gentz, Steven M. Ruben
  • Keratinocyte growth factor-2
    Publication number: 20040224387
    Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.
    Type: Application
    Filed: December 12, 2003
    Publication date: November 11, 2004
    Applicant: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Pablo Jimenez, D. Roxanne Duan, Mark A. Rampy, Donna Mendrick, Jun Zhang, Jian Ni, Paul A. Moore, Timothy A. Coleman, Joachim R. Gruber, Patrick J. Dillon, Reiner L. Gentz
  • Human monocyte colony inhibitory factor (M-CIF) polypeptides
    Patent number: 6811773
    Abstract: There are disclosed therapeutic compositions and methods using a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-&ggr; chemokine &bgr;1(CK&bgr;1 or ckb-1)), as well as ioslated nucleic acid molecules encoding M-CIF, and vectors, host cells and recombinant methods for producing the same.
    Type: Grant
    Filed: May 15, 2000
    Date of Patent: November 2, 2004
    Assignee: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Brent L. Kreider, Jun Zhang, Michael Antonaccio, Donna Mendrick, Pablo Jimenez, Vikram Patel, Craig A. Rosen, Mark D. Adams, Haodong Li, Steven M. Ruben
  • Human tumor necrosis factor receptor TR9
    Publication number: 20040197870
    Abstract: The present invention relates to a novel member of the tumor necrosis factor family of receptors. In particular, isolated nucleic acid molecules are provided encoding the human TR9 receptor. TR9 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR9 receptor activity.
    Type: Application
    Filed: April 30, 2004
    Publication date: October 7, 2004
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Guo-Liang Yu, Ping Fan, Reiner L. Gentz
  • Cytostatin II
    Publication number: 20040185505
    Abstract: The invention relates to cytostatin II growth modulatory polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.
    Type: Application
    Filed: April 13, 2004
    Publication date: September 23, 2004
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Guo-Liang Yu, Reiner L. Gentz
  • Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)
    Publication number: 20040152169
    Abstract: There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine &bgr;8 (CK&bgr;8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-&ggr; and chemokine &bgr;1 (CK&bgr;1 or ckb-1)), and a macrophage inhibitory protein-4 (MIP-4), as well as MPIF-1, M-CIF and/or MIP-4 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same.
    Type: Application
    Filed: July 25, 2003
    Publication date: August 5, 2004
    Applicant: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Brent L. Kreider, Jun Zhang, Michael Antonaccio, Donna Mendrick, Pablo Jimenez, Vikram Patel, Craig A. Rosen, Mark D. Adams, Haodong Li, Steven M. Ruben
  • T1 receptor-like ligand II
    Publication number: 20040146501
    Abstract: The present invention concerns a novel T1R-like ligand II protein. In particular, isolated nucleic acid molecules are provided encoding the T1R-like ligand II protein. T1R-like ligand II polypeptides are also provided, as are recombinant vectors and host cells for expressing the same.
    Type: Application
    Filed: October 27, 2003
    Publication date: July 29, 2004
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Steven M. Ruben
  • Fc receptors and polypeptides
    Publication number: 20040147733
    Abstract: The present invention relates to four novel Fc receptor-like proteins which are members of the Fc Receptor family. In particular, isolated nucleic acid molecules are provided encoding the human FcR-I, FcR-II, FcR-III, and FcR-IV proteins. FcR-I, FcR-II, FcR-III, and FcR-IV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of FcR-I, FcR-II, FcR-III, and FcR-IV activities. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
    Type: Application
    Filed: February 5, 2004
    Publication date: July 29, 2004
    Applicant: Human Genome Sciences, Inc.
    Inventors: Henrik S. Olsen, Jian Ni, Marianne Murphy, Steven M. Ruben, Reiner L. Gentz
  • Death domain containing receptor 5
    Publication number: 20040141952
    Abstract: The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.
    Type: Application
    Filed: February 10, 2004
    Publication date: July 22, 2004
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Guo-Liang Yu, Craig A. Rosen
  • T1-R ligand III
    Publication number: 20040138443
    Abstract: The present invention relates to a novel T1-R ligand III protein which is a member of the IL-1RI ligand-like family. In particular, isolated nucleic acid molecules are provided encoding the human T1-R ligand III protein. T1-R ligand III polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of T1-R ligand III activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
    Type: Application
    Filed: February 11, 2004
    Publication date: July 15, 2004
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Steven M. Ruben